ER004

BIOLOGICAL2 trials

Sponsors

Pierre Fabre Medicament, Fondation EspeRare, EspeRare Foundation

Conditions

X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)X-linked hypohidrotic ectodermal dysplasia (XLHED)

Phase 2

Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia

RecruitingNCT04980638

EspeRare FoundationX-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)

Start: 2022-04-26End: 2032-12-31Target: 20Updated: 2025-04-30

A prospective, open-label, genotype-match controlled, multicenter clinical trial to investigate the efficacy and safety of intra-amniotic ER004 as a prenatal treatment for male subjects with X-linked hypohidrotic ectodermal dysplasia (XLHED)

RecruitingCTIS2024-512632-30-00

Pierre Fabre Medicament, Fondation EspeRareX-linked hypohidrotic ectodermal dysplasia (XLHED)

Start: 2021-12-02Target: 11Updated: 2025-11-07